(-1.20%) 5 046.00 points
(-1.13%) 38 243 points
(-1.57%) 17 387 points
(0.22%) $82.99
(-1.09%) $1.635
(0.15%) $2 341.90
(0.75%) $27.55
(-0.33%) $912.80
(0.14%) $0.936
(0.25%) $11.01
(-0.05%) $0.802
(-0.64%) $91.73
Live Chart Being Loaded With Signals
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis...
Stats | |
---|---|
Today's Volume | 279 880 |
Average Volume | 23 031.00 |
Market Cap | 30 173.00 |
EPS | €0 ( 2024-04-19 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 0 |
ATR14 | €0.00600 (4.35%) |
Pharnext SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharnext SA Financials
Annual | 2022 |
Revenue: | €558.00 |
Gross Profit: | €2.26M (404 643.19 %) |
EPS: | €-8.32 |
Q2 | 2023 |
Revenue: | €150 000 |
Gross Profit: | €763 025 (508.68 %) |
EPS: | €-69 969 278 |
Q4 | 2022 |
Revenue: | €1.06M |
Gross Profit: | €689 450 (65.22 %) |
EPS: | €-26.27 |
Q2 | 2022 |
Revenue: | €558.00 |
Gross Profit: | €1.20M (215 193.01 %) |
EPS: | €-222 250 000 000 000 |
Financial Reports:
No articles found.
Pharnext SA
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators